Istvan Karpati
Overview
Explore the profile of Istvan Karpati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kiraly E, Szollosi G, Jenei Z, Balla J, Karpati I
Ren Fail
. 2024 Jun;
46(2):2370439.
PMID: 38938194
Background: Chronic kidney disease (CKD) poses a significant public health challenge globally while impacting patients' physical function and quality of life. Addressing the issues of physical inactivity and pain management...
2.
Kiraly E, Szollosi G, Jenei Z, Karpati I
Ren Fail
. 2024 Mar;
46(1):2324079.
PMID: 38425087
Background: Patients with end-stage kidney disease (ESKD) receiving peritoneal dialysis (PD) or haemodyalisis (PD) appear to be less physically active than healthy persons, a situation that could lead to reductions...
3.
Ladanyi E, Salfer B, Balla J, Karpati I, Reusz G, Szabo L, et al.
Int J Public Health
. 2023 Sep;
68:1606151.
PMID: 37705761
Recognition of chronic kidney disease (CKD) is crucial in type 2 diabetes mellitus (T2DM). We conducted a nationwide epidemiological study to evaluate T2DM-associated CKD in Hungary between 2016 and 2020....
4.
Varga E, Seres I, Harangi M, Karpati I, Koncsos P, Sztanek F, et al.
Kidney Blood Press Res
. 2012 Mar;
35(4):265-72.
PMID: 22378349
Background/aims: Human paraoxonase-1 (PON1) is responsible for the antioxidant effect of high-density lipoprotein (HDL) by inhibiting low-density lipoprotein oxidation. Previous studies discovered dyslipidemia (DL) and decreased PON1 activity in chronic...
5.
Paragh G, Seres I, Harangi M, Pocsai Z, Asztalos L, Locsey L, et al.
Nephron Clin Pract
. 2009 Jul;
113(1):c46-53.
PMID: 19602899
Background: Human serum paraoxonase-1 (PON1) is a high-density lipoprotein-associated ester hydrolase which can inhibit low-density lipoprotein oxidation and has an antiatherogenic effect. Two common polymorphisms are known in the PON1...
6.
Varga E, Seres I, Harangi M, Sztanek F, Asztalos L, Locsey L, et al.
Dis Markers
. 2009 Jul;
26(3):141-8.
PMID: 19597297
Background: Human paraoxonase-1 (PON1) inhibits LDL-oxidation and atherogenesis, and possesses lactonase activity. Decreased PON1 activity was found in hemodialyzed and renal transplanted patients. Cystatin C plays a protective role in...
7.
Katko M, Kiss I, Karpati I, Kadar A, Matyus J, Csongradi E, et al.
Biol Trace Elem Res
. 2008 May;
124(3):195-205.
PMID: 18465090
Severe hyperhomocysteinemia (HHC) is associated with atherosclerosis. In hemodialysis (HD) patients, one of the main causes of death is cardiovascular disease. In animals, trace elements such as cobalt, copper, iron,...
8.
Matyus J, Olah A, Ujhelyi L, Karpati I, Balla J
Orv Hetil
. 2007 Dec;
149(2):77-82.
PMID: 18093898
Nowadays chronic kidney disease has become a major public health problem due to the great increase in atherogenic nephropathies. In the absence of classic renal symptoms, chronic kidney disease is...
9.
Effects of tocopherols and 2,2'-carboxyethyl hydroxychromans on phorbol-ester-stimulated neutrophils
Varga Z, Kosaras E, Komodi E, Katko M, Karpati I, Balla J, et al.
J Nutr Biochem
. 2007 Aug;
19(5):320-7.
PMID: 17683924
Tocopherol vitamers [e.g., alpha-, gamma- and delta-tocopherol (alpha-TOC, gamma-TOC and delta-TOC, respectively)] and their water-soluble 2,2'-carboxyethyl hydroxychroman metabolites (e.g., alpha-, gamma- and delta-CEHC) all possess antioxidant properties. As a consequence,...
10.
Varga Z, Paragh G, Seres I, Kakuk G, Karanyi Z, Karpati I, et al.
Nephron Clin Pract
. 2006 Mar;
103(3):c114-20.
PMID: 16534235
Background: Exogenous leptin markedly decreased plasma paraoxonase (PON1) activity in rats. Hyperleptinemia and decreased PON1 activity have previously been demonstrated in uremia. Therefore, we investigated the relationship between leptin level...